We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byLena Glasco
Modified over 2 years ago
©2011 MFMER | slide-1 Continuous Renal-Replacement Therapy CRRT Kianoush Kashani 5 th Anesthesia and Critical Care Conference Kuwait 2013
©2011 MFMER | slide-2 RRT indications (traditional) Gibney et al. cJASN 3: , 2008.
©2011 MFMER | slide-3 RRT Support pt and effects of complications from MOF Improve metabolic milieu for Increasing survival Recovery of multiple organ systems Volume overload without oligoanuria or azotemia CHF Postoperative Withhold RRT If return of renal function is likely Conservative management likely to succeed
©2011 MFMER | slide-4 MultiOrgan Support Therapy (MOST)
©2011 MFMER | slide-5 Heart
©2011 MFMER | slide-6 MOST: Cardiac Support Uncontrolled studies improve myocardial elastance with HF and adequate fluid balance UNLOAD Trial (Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure) RCT, multicenter, (N=200) excluded sCR > 3 mg/dL Improved 48-hours weight loss re-hospitalization rates and ED visits at 90 days diuretic responsiveness No change in mortality, CHF class and QOL Costanzo et al. J Am Coll Cardiol 49:675–683, 2007
©2011 MFMER | slide-7 Liver
©2011 MFMER | slide-8 Liver extracorporeal support therapies Non-cell based RRT (IRRT, CRRT, SLED) Hemoperfusion, hemoabsorption Plasma exchange Plasmaphoresis, Plasma filtration absorption, Selective plasma filtration technology (SEPET) Albumin based Molecular adsorbent recirculating system (MARS) Single pass albumin dialysis (SPAD) Cell-based synthetic function Human hepatocytes Porcine hepatocytes Cerda et al. Seminars in DialysisVol 24, No –202
©2011 MFMER | slide-9 Cell-based Liver Purposes Detoxification Provide synthetic Provide regulatory functions Cell sources Primary porcine hepatocytes Immunologic reactions Immortalized human cells Rare source Loose their liver function by time Cells derived from hepatic tumors Fear of tumorgenicity Small single-center phase I and II trials Proof of principle Cerda et al. Seminars in DialysisVol 24, No –202
©2011 MFMER | slide-10 Sepsis
©2011 MFMER | slide-11 Systemic Inflammatory Response Syndrome (SIRS) Vs. Compensatory Anti-inflammatory Response Syndrome (CARS)
©2011 MFMER | slide-12 Sepsis management - MOST HVHF High cut-off hemofilters Hemoadsorption Non-specific Charcoal Resin Plasma filtration coupled with adsorption (CPFA) Improved MAP Decrease the need for norepinephrine Grootendorst et al.J Crit Care 1992;7:67–75. Bellomo et al: Intensive CareMed 29:1222–1228, 2003
©2011 MFMER | slide-13 HICOSS trial (High Cut-Off Sepsis study) N = 120 Septic shock with AKI Conventional membrane vs. HCO membrane (cut-off of 60 kD) 5 days on CVVHD Stopped prematurely after 81 patients No difference in 28-day mortality (31% vs. 33%) No difference in vasopressor need, MV, or LOS No difference in albumin levels Honore et al. Proc 10th WFSCICCM,Florence, Italy, 2009.
©2011 MFMER | slide-14 Sepsis management - MOST Specific Polymyxin B EUPHAS trial (single center_Italy) Improve MAP/vasopressor use PaO2 FIO2 Mortality and SOFA EUPHRATES trial (multicenter_US) Cruz et al. JAMA. 2009;301(23): Ding et al. ASAIO Journal 2011; 57:426 – 432.
©2011 MFMER | slide-15 Lung
©2011 MFMER | slide-16 Respiratory support Refractory ARDS TV decreased from 6ml/kg to 4 ml/kg Terragni et al. Anesthesiology 2009; 111:826–35
©2011 MFMER | slide-17 RRT modalities
©2011 MFMER | slide-18 Modalities of RRT Hemodyalisis IRRT CRRT Peritoneal dialysis Transplant
©2011 MFMER | slide-19 RRT modality and mortality Bagshaw et al. Crit Care Med 2008 Vol. 36, No. 2
©2011 MFMER | slide-20 Renal recovery Evidence for CRRT benefit on renal recovery Strong physiologic rationale Observational studies Epidemiologic studies (n=3000) No benefit found in RCTs All RCTs have significant limitations
©2011 MFMER | slide-21 Cost Mayo Clinic study N= 161, retrospective observational study Mean adjusted total costs through hospital discharge $ for IHD $140,733 for CRRT (P<.001). Rauf et al. J Intensive Care Med May-Jun;23(3):
©2011 MFMER | slide-22 Anticoagulation
©2011 MFMER | slide-23 Case 65 yo with PMH of ESLD, DM, HTN Presented with sepsis, DIC, AKI Started on CVVH for AKI stage III Qb 200 ml/min RF 4500 ml/h Citrate 300 ml/h 22 mEq/L Bicarbonate Prismasate ® bath Her dialyzer clots every four hours What to do?
©2011 MFMER | slide-24 CVVH -predilution Partial loss of delivered RF by HF need for anticoagulation AccessReturn UF Flow Replacement fluid
©2011 MFMER | slide-25 CVVH -postdilution Higher clearance chance of clotting AccessReturn UF Flow Replacement fluid
©2011 MFMER | slide-26 Effect of filtration on CVVH Hematocrit 30% Hematocrit 60% Maintain filtration fraction at 25%
©2011 MFMER | slide-27 Case Filtration fraction = [ Q uf (ml/min) / Q b (ml/min)] X 100 Q uf = 4500 ml/hour = 4500/60 = 75 ml/min Q b = 200 ml/min Current FF = (75/200) X 100 = 37.5% 1.Decrease Q uf to 3000 ml/hour (50 ml/min) 2.Increase Q b to 300 ml/min FF = 50/200 X 100 = 25% FF = 75/300 X 100 = 25%
©2011 MFMER | slide-28 Anticoagulation: Options No Heparin protocols Heparin Unfractionated LMWH Citrate Others Prostacyclin Danaparoid Hirudin/argatroban Nafamostate mesylate
©2011 MFMER | slide-29 No Heparin Systemically Heparinized Gail Annich, University of Michigan Citrate
©2011 MFMER | slide-30 Citrate Vs. Heparin Zhang et al. Intensive Care Med (2012) 38:20–28 Filter life spanRisk of bleeding
©2011 MFMER | slide-31 CRRT dosing
©2011 MFMER | slide-32 Meta-analysis Mortality Jun et al. Clin J Am Soc Nephrol 5: 956–963, 2010.
©2011 MFMER | slide-33 Meta-analysis Renal recovery Jun et al. Clin J Am Soc Nephrol 5: 956–963, 2010.
©2011 MFMER | slide-34 CRRT Timing
©2011 MFMER | slide-35 Early versus late RRT (Mortality) Karvellas et al. Critical Care 2011, 15:R72
©2011 MFMER | slide-36 Early versus late RRT (Mortality) Karvellas et al. Critical Care 2011, 15:R72
©2011 MFMER | slide-37 Early versus late RRT (RRT independence) Karvellas et al. Critical Care 2011, 15:R72
©2011 MFMER | slide-38 شكراً The best interest of the patient is the only interest to be considered
©2011 MFMER | slide-39 Questions & Discussion
Haemofiltration In Sepsis Tom Owen Mar Overview Rationale for CVVH use in sepsis Evidence of effectiveness Newer therapies Summary.
Is There a Rationale To Use CRRT For Treating Sepsis? James D. Fortenberry MD, FCCM, FAAP Pediatrician in Chief Children’s Healthcare of Atlanta Professor.
ROLE OF CRRT IN SEPSIS Dr Apoorva Jain Agra. SEPSIS: BACKGROUND Severe Sepsis and Septic Shock are the primary causes of Multiple Organ Dysfunction.
PSSA Preparation. Question 1(no calculator) D Question 2 (no calculator)
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
25 seconds left….. 24 seconds left….. 23 seconds left…..
Andrew Durward London 2015 Haemofiltration for sepsis: burial or resurrection?
PCRRT on ECMO Norma J Maxvold Pediatric Critical Care.
Renal Intensive Care. Rivers, E. P. et al. CMAJ 2005;173: Sepsis – The “ real milieu ” Sepsis.
Chapter 11 Membrane Structure Essential Cell Biology Third Edition Copyright © Garland Science 2010.
Scenario: EOT/EOT-R/COT Resident admitted March 10th Admitted for PT and OT following knee replacement for patient with CHF, COPD, shortness of breath.
BMU - E I 1 Development of renewable energy sources in Germany in
WEEK 1 You have 10 seconds to name…
Copyright © 2003 Pearson Education, Inc. Slide 1 Computer Systems Organization & Architecture Chapters 8-12 John D. Carpinelli.
Addition 1’s to
1 Prof. Valter Bezerra Dantas
×1= 9 4 1×1= 1 5 8×1= 8 6 7×1= 7 7 8×3= 24.
© 2012 National Heart Foundation of Australia. Slide 2.
WHEN TO CONSIDER RRT Timothy E Bunchman Founder PCRRT
©Brooks/Cole, 2001 Chapter 12 Derived Types-- Enumerated, Structure and Union.
경희대 호흡기내과 ACUTE RESPIRATORY DISTRESS SYNDROME (Update 2013) 호흡기내과 박명재.
Basel-ICU-Journal Challenge18/20/ Basel-ICU-Journal Challenge8/20/2014.
BMU – KI III 1 Development of renewable energy sources in Germany in
Jeopardy Topic 1Topic Q 1Q 6Q 11Q 16Q 21 Q 2Q 7Q 12Q 17Q 22 Q 3Q 8Q 13Q 18Q 23 Q 4Q 9Q 14Q 19Q 24 Q 5Q 10Q 15Q 20Q 25 Final Jeopardy.
Addition Facts = = =
McDonald’s calendar 2009 January
Major Clinical Trials in AKI Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Murach's PHP and MySQL, C15© 2010, Mike Murach & Associates, Inc.Slide 1.
Journal Club: AKI and timing of RRT in Post-op ITU Patients Dr Andrew Stein Consultant in Renal and Acute Medicine UHCW, Coventry.
Major Published Clinical Trials in AKI: What do they Really Mean? Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Time for a BREAK! You have 45 Minutes. Time Left 44.
Copyright © 2011, Elsevier Inc. All rights reserved. Chapter 2 Author: Julia Richards and R. Scott Hawley.
REVIEW: Arthropod ID. 1. Name the subphylum. 2. Name the subphylum. 3. Name the order.
Chapter 15 Intracellular Compartments and Transport Essential Cell Biology Third Edition Copyright © Garland Science 2010.
Year 6 mental test 10 second questions Addition and Subtraction Addition.
FACTORING Think unfoil Work down, Show all steps ax 2 + bx + c.
CALENDAR NEW CALENDAR
Continuous Renal Replacement Therapy Kelly Monaghan, DVM Small Animal Internal Medicine August 28, 2009.
Acute Kidney Injury & Sepsis Patrick D Brophy, MD, MHCDS Director Pediatric Nephrology Professor The University of Iowa London 2015.
EU Market Situation for Eggs and Poultry Management Committee 21 June 2012.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
Copyright © Action Works 2008 All Rights Reserved - Photos by David D. Kempster 1.
Risposta infiammatoria - Dove siamo? - InfectionSepsis Severe Sepsis MODS Death SIRS = Systemic inflammatory response syndrome CARS = Compensatory anti-inflammatory.
We will resume in: 25 Minutes We will resume in: 24 Minutes.
Factor P (8-5ab) 2. 4(d² + 4) 3. 3rs(2r – s) 4. 15cd(1 + 2cd) 5. 8(4a² + 3b²) 6. 12xy(3y – 4x) 7. 5x²y(6x + 7y) 8. 3cd²(3c² - 2d) 9. 15bc³(5b +
Model and Relationships 6 M 1 M M M M M M M M M M M M M M M M
Chapter 10 Analyzing Genes and Genomes Essential Cell Biology Third Edition Copyright © Garland Science 2010.
© 2017 SlidePlayer.com Inc. All rights reserved.